Cargando…

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

BACKGROUND: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer. METHODS: Patients previously untreated for metastatic disease were randomized in: group A (irinotecan, capecitabine, bevacizumab, eve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pectasides, Dimitrios, Papaxoinis, George, Kalogeras, Konstantine T, Eleftheraki, Anastasia G, Xanthakis, Ioannis, Makatsoris, Thomas, Samantas, Epaminondas, Varthalitis, Ioannis, Papakostas, Pavlos, Nikitas, Nikitas, Papandreou, Christos N, Pentheroudakis, George, Timotheadou, Eleni, Koutras, Angelos, Sgouros, Joseph, Bafaloukos, Dimitrios, Klouvas, George, Economopoulos, Theofanis, Syrigos, Konstantinos N, Fountzilas, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466131/ https://www.ncbi.nlm.nih.gov/pubmed/22748098 http://dx.doi.org/10.1186/1471-2407-12-271

Ejemplares similares

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2014)

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study
por: Papaxoinis, George, et al.
Publicado: (2015)

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
por: Pectasides, Dimitrios, et al.
Publicado: (2015)

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
por: Fountzilas, George, et al.
Publicado: (2014)

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
por: Gogas, Helen, et al.
Publicado: (2016)

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
por: Fountzilas, George, et al.
Publicado: (2012)

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
por: Fountzilas, George, et al.
Publicado: (2013)

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study
por: Koutras, Angelos, et al.
Publicado: (2015)

The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial
por: Linardou, Helena, et al.
Publicado: (2012)

Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab
por: Economopoulou, Panagiota, et al.
Publicado: (2019)

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
por: Papadimitriou, Christos A, et al.
Publicado: (2011)

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
por: Pentheroudakis, George, et al.
Publicado: (2013)

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy
por: Tsiatas, Marinos, et al.
Publicado: (2018)

Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial
por: Pentheroudakis, George, et al.
Publicado: (2015)

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013)

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
por: Briasoulis, Evangelos, et al.
Publicado: (2013)

Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2013)

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
por: Fountzilas, George, et al.
Publicado: (2012)

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
por: Bafaloukos, Dimitrios, et al.
Publicado: (2010)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative
por: Fountzilas, Elena, et al.
Publicado: (2020)

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019)

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy
por: Timotheadou, Eleni, et al.
Publicado: (2017)

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study
por: Koutras, Angelos, et al.
Publicado: (2018)

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
por: Fountzilas, George, et al.
Publicado: (2016)

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials
por: Kotoula, Vassiliki, et al.
Publicado: (2015)

Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study
por: Stavridi, Flora, et al.
Publicado: (2016)

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group
por: Psyrri, Amanda, et al.
Publicado: (2017)

Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
por: Razis, Evangelia, et al.
Publicado: (2008)

Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab
por: Mountzios, G, et al.
Publicado: (2019)

Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes
por: Mountzios, Giannis, et al.
Publicado: (2014)

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies
por: Koletsa, Triantafyllia, et al.
Publicado: (2014)

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
por: Kotaka, Masahito, et al.
Publicado: (2016)

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma
por: Fountzilas, Elena, et al.
Publicado: (2021)

Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
por: Kourea, Helen P., et al.
Publicado: (2022)

Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases
por: Stavropoulou, Alexandra V., et al.
Publicado: (2013)

Correction: Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases
por: Stavropoulou, Alexandra V., et al.
Publicado: (2013)

Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial
por: Goussia, Anna, et al.
Publicado: (2018)

A Successfully Resected Case of Recurrent Lung and Liver Metastases of Rectal Cancer Treated with XELIRI + Bevacizumab Therapy
por: Aisu, Naoya, et al.
Publicado: (2013)

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
por: Aravantinos, Gerasimos, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ubar0piuqhfhr0jti87k3267ua